Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens

Davide Bedognetti, Gabriele Zoppoli, Carlotta Massucco, Elisa Zanardi, Simonetta Zupo, Andrea Bruzzone, Mario Roberto Sertoli, Enrico Balleari, Omar Racchi, Marco Messina, Graziano Caltabiano, Giancarlo Icardi, Paolo Durando, Francesco M. Marincola, Francesco Boccardo, Manlio Ferrarini, Filippo Ansaldi, Andrea De Maria

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Influenza vaccination is generally recommended for non-Hodgkin's lymphoma (NHL) patients, but no data are available about the activity of this vaccine after treatment with rituximab-containing regimens. We evaluated the humoral response to the trivalent seasonal influenza vaccine in a group of NHL patients in complete remission for ≥6 mo (median, 29 mo) after treatment with rituximab-containing regimens (n = 31) compared with age-matched healthy subjects (n = 34). B cell populations and incidence of influenza-like illness were also evaluated. For each viral strain, the response was significantly lower in patients compared with controls and was particularly poor in patients treated with fludarabine-based regimens. In the patient group, the response to vaccination did not fulfill the immunogenic criteria based on the European Committee for Medicinal Products for Human Use requirements. Among the patients, CD27+ memory B cells were significantly reduced, and their reduction correlated with serum IgM levels and vaccine response. Episodes of influenza-like illness were recorded only in patients. These results showed that NHL patients treated with rituximab-containing regimens have persisting perturbations of B cell compartments and Ig synthesis and may be at particular risk for infection, even in long-standing complete remission.

Original languageEnglish
Pages (from-to)6044-6055
Number of pages12
JournalJournal of Immunology
Volume186
Issue number10
DOIs
Publication statusPublished - 15 May 2011
Externally publishedYes

Fingerprint

Influenza Vaccines
Non-Hodgkin's Lymphoma
B-Lymphocytes
Human Influenza
Vaccination
Vaccines
Rituximab
Immunoglobulin M
Healthy Volunteers
Incidence
Therapeutics
Infection
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. / Bedognetti, Davide; Zoppoli, Gabriele; Massucco, Carlotta; Zanardi, Elisa; Zupo, Simonetta; Bruzzone, Andrea; Sertoli, Mario Roberto; Balleari, Enrico; Racchi, Omar; Messina, Marco; Caltabiano, Graziano; Icardi, Giancarlo; Durando, Paolo; Marincola, Francesco M.; Boccardo, Francesco; Ferrarini, Manlio; Ansaldi, Filippo; De Maria, Andrea.

In: Journal of Immunology, Vol. 186, No. 10, 15.05.2011, p. 6044-6055.

Research output: Contribution to journalArticle

Bedognetti, D, Zoppoli, G, Massucco, C, Zanardi, E, Zupo, S, Bruzzone, A, Sertoli, MR, Balleari, E, Racchi, O, Messina, M, Caltabiano, G, Icardi, G, Durando, P, Marincola, FM, Boccardo, F, Ferrarini, M, Ansaldi, F & De Maria, A 2011, 'Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens', Journal of Immunology, vol. 186, no. 10, pp. 6044-6055. https://doi.org/10.4049/jimmunol.1004095
Bedognetti, Davide ; Zoppoli, Gabriele ; Massucco, Carlotta ; Zanardi, Elisa ; Zupo, Simonetta ; Bruzzone, Andrea ; Sertoli, Mario Roberto ; Balleari, Enrico ; Racchi, Omar ; Messina, Marco ; Caltabiano, Graziano ; Icardi, Giancarlo ; Durando, Paolo ; Marincola, Francesco M. ; Boccardo, Francesco ; Ferrarini, Manlio ; Ansaldi, Filippo ; De Maria, Andrea. / Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. In: Journal of Immunology. 2011 ; Vol. 186, No. 10. pp. 6044-6055.
@article{40d6ebe4e01e4d5b83f70305d694407c,
title = "Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens",
abstract = "Influenza vaccination is generally recommended for non-Hodgkin's lymphoma (NHL) patients, but no data are available about the activity of this vaccine after treatment with rituximab-containing regimens. We evaluated the humoral response to the trivalent seasonal influenza vaccine in a group of NHL patients in complete remission for ≥6 mo (median, 29 mo) after treatment with rituximab-containing regimens (n = 31) compared with age-matched healthy subjects (n = 34). B cell populations and incidence of influenza-like illness were also evaluated. For each viral strain, the response was significantly lower in patients compared with controls and was particularly poor in patients treated with fludarabine-based regimens. In the patient group, the response to vaccination did not fulfill the immunogenic criteria based on the European Committee for Medicinal Products for Human Use requirements. Among the patients, CD27+ memory B cells were significantly reduced, and their reduction correlated with serum IgM levels and vaccine response. Episodes of influenza-like illness were recorded only in patients. These results showed that NHL patients treated with rituximab-containing regimens have persisting perturbations of B cell compartments and Ig synthesis and may be at particular risk for infection, even in long-standing complete remission.",
author = "Davide Bedognetti and Gabriele Zoppoli and Carlotta Massucco and Elisa Zanardi and Simonetta Zupo and Andrea Bruzzone and Sertoli, {Mario Roberto} and Enrico Balleari and Omar Racchi and Marco Messina and Graziano Caltabiano and Giancarlo Icardi and Paolo Durando and Marincola, {Francesco M.} and Francesco Boccardo and Manlio Ferrarini and Filippo Ansaldi and {De Maria}, Andrea",
year = "2011",
month = "5",
day = "15",
doi = "10.4049/jimmunol.1004095",
language = "English",
volume = "186",
pages = "6044--6055",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens

AU - Bedognetti, Davide

AU - Zoppoli, Gabriele

AU - Massucco, Carlotta

AU - Zanardi, Elisa

AU - Zupo, Simonetta

AU - Bruzzone, Andrea

AU - Sertoli, Mario Roberto

AU - Balleari, Enrico

AU - Racchi, Omar

AU - Messina, Marco

AU - Caltabiano, Graziano

AU - Icardi, Giancarlo

AU - Durando, Paolo

AU - Marincola, Francesco M.

AU - Boccardo, Francesco

AU - Ferrarini, Manlio

AU - Ansaldi, Filippo

AU - De Maria, Andrea

PY - 2011/5/15

Y1 - 2011/5/15

N2 - Influenza vaccination is generally recommended for non-Hodgkin's lymphoma (NHL) patients, but no data are available about the activity of this vaccine after treatment with rituximab-containing regimens. We evaluated the humoral response to the trivalent seasonal influenza vaccine in a group of NHL patients in complete remission for ≥6 mo (median, 29 mo) after treatment with rituximab-containing regimens (n = 31) compared with age-matched healthy subjects (n = 34). B cell populations and incidence of influenza-like illness were also evaluated. For each viral strain, the response was significantly lower in patients compared with controls and was particularly poor in patients treated with fludarabine-based regimens. In the patient group, the response to vaccination did not fulfill the immunogenic criteria based on the European Committee for Medicinal Products for Human Use requirements. Among the patients, CD27+ memory B cells were significantly reduced, and their reduction correlated with serum IgM levels and vaccine response. Episodes of influenza-like illness were recorded only in patients. These results showed that NHL patients treated with rituximab-containing regimens have persisting perturbations of B cell compartments and Ig synthesis and may be at particular risk for infection, even in long-standing complete remission.

AB - Influenza vaccination is generally recommended for non-Hodgkin's lymphoma (NHL) patients, but no data are available about the activity of this vaccine after treatment with rituximab-containing regimens. We evaluated the humoral response to the trivalent seasonal influenza vaccine in a group of NHL patients in complete remission for ≥6 mo (median, 29 mo) after treatment with rituximab-containing regimens (n = 31) compared with age-matched healthy subjects (n = 34). B cell populations and incidence of influenza-like illness were also evaluated. For each viral strain, the response was significantly lower in patients compared with controls and was particularly poor in patients treated with fludarabine-based regimens. In the patient group, the response to vaccination did not fulfill the immunogenic criteria based on the European Committee for Medicinal Products for Human Use requirements. Among the patients, CD27+ memory B cells were significantly reduced, and their reduction correlated with serum IgM levels and vaccine response. Episodes of influenza-like illness were recorded only in patients. These results showed that NHL patients treated with rituximab-containing regimens have persisting perturbations of B cell compartments and Ig synthesis and may be at particular risk for infection, even in long-standing complete remission.

UR - http://www.scopus.com/inward/record.url?scp=79956210768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956210768&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1004095

DO - 10.4049/jimmunol.1004095

M3 - Article

C2 - 21498665

AN - SCOPUS:79956210768

VL - 186

SP - 6044

EP - 6055

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -